PYXIS ONCOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.38 USD | -0.68% |
|
+1.86% | +143.33% |
| 03-22 | H.C. Wainwright Adjusts Price Target on Pyxis Oncology to $7 From $4, Maintains Buy Rating | MT |
| 03-21 | Health Care Up on Drug Sales Optimism -- Health Care Roundup | DJ |
Chart calendar Pyxis Oncology, Inc.
a4c73a2908a3da8f4e49edfb743d70.fU36gdU8R0Cb_aeCp-0tgtETKmzcbizQk-eObQRTaIM.BX-ptJxvNnH_ivXW74odt-dEWQvlAEuH9ovIGncpN-xJfp745n1wK8qYnw~f0c7a501aca97e3a2399f5f0a5422bb0
Upcoming events on Pyxis Oncology, Inc.
Past events on Pyxis Oncology, Inc.
| 16/04/2024 18:30 | Stifel Virtual Targeted Oncology Days Conference |
| 08/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: 2908 |
| 08/04/2024 17:00 | American Association for Cancer Research Meeting - Abstract Number: 1373 |
| 07/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: 742 |
| 07/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: 177 |
| 21/03/2024 11:30 | Q4 2023 Earnings Release |
| 13/03/2024 12:40 | Leerink Partners Global Biopharma Conference |
| 18/01/2024 18:00 | B. Riley Securities Oncology Conference - Track 2 |
| 16/11/2023 12:30 | Jefferies London Healthcare Conference |
| 07/11/2023 21:30 | Q3 2023 Earnings Release |
| 04/11/2023 22:20 | Society for Immunotherapy of Cancer Meeting - Poster Number: 1361 |
| 04/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Poster Number: 572 |
| 04/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Poster Number: 756 |
| 04/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Poster Number: 762 |
| 31/10/2023 | Society for Immunotherapy of Cancer Meeting |
| 04/10/2023 16:00 | RBC Antibody Drug Conjugate Day |
| 11/09/2023 12:00 | H.C. Wainwright Global Investment Conference |
| 11/08/2023 12:00 | Q2 2023 Earnings Release |
| 07/08/2023 20:00 | BTIG Virtual Biotechnology Conference |
| 13/06/2023 15:00 | Annual General Meeting |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,17 - | 4,50 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -69,1 -65,6 -5.37% | -123 -119 -3.35% | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -69,7 -66,0 -5.65% | -123 -117 -5.39% | -82,2 -86,2 4.65% | -68,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -76,0 -70,1 -8.41% | -121 -116 -3.95% | -73,8 -79,3 6.92% | -43,1 |
|
Net income Million USD | Released Forecast Spread | -12,8 | -76,0 -69,6 -9.2% | -121 -116 -3.95% | -73,8 -79,8 7.56% | -43,1 |
|
EPS USD | Released Forecast Spread | -1,96 | -2,31 -3,07 24.65% | -3,65 -3,73 2.01% | -1,85 -1,95 5.25% | -0,76 |
| Announcement Date | 21/06/21 | 29/03/22 | 22/03/23 | 21/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,83 - | 0,00 0,00 - | 0,00 0,17 - | 4,13 | 0,13 | 0,13 | 0,13 | 0,50 |
|
EBITDA Million USD | Released Forecast Spread | -16,3 -13,1 -24.09% | -31,2 -20,2 -54.61% | -25,6 -28,1 9.16% | -28,2 -32,8 13.91% | -37,8 -39,0 3.22% | -17,6 -24,6 28.39% | ||||||||
|
EBIT Million USD | Released Forecast Spread | -16,4 -12,7 -29.36% | -31,4 -21,9 -43.26% | -25,7 -24,5 -4.83% | -28,4 -27,0 -4.97% | -38,0 -31,7 -19.96% | -21,0 -29,0 27.84% | -18,1 -24,3 25.51% | -25,4 -22,3 -13.46% | -17,8 -21,7 17.97% | -13,4 | -18,1 | -18,4 | -18,4 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -16,8 -12,5 -34.5% | -31,4 -23,9 -31.3% | -25,6 -16,8 -52.15% | -27,7 -25,9 -6.84% | -36,1 -29,5 -22.53% | -19,2 -28,0 31.36% | -15,9 -23,8 33.07% | -23,0 -23,0 -0.21% | -15,6 -21,1 26.19% | -10,4 | -13,2 | -10,2 | -9,75 | |
|
Net income Million USD | Released Forecast Spread | -16,8 -12,3 -36.81% | -31,4 -23,6 -32.88% | -25,6 -19,8 -29.36% | -27,7 -23,9 -15.8% | -36,1 -29,3 -23.36% | -19,2 -28,7 32.97% | -15,9 -24,0 33.75% | -23,0 -23,0 -0.21% | -15,6 -21,7 28.01% | -10,4 | -13,2 | -10,2 | -9,75 | |
|
EPS USD | Released Forecast Spread | -0,57 -0,38 -50% | -0,97 -0,64 -51.56% | -0,79 -0,85 6.69% | -0,85 -0,82 -3.66% | -1,04 -0,97 -7.22% | -0,54 -0,93 42.14% | -0,41 -0,62 33.51% | -0,56 -0,44 -27.27% | -0,33 -0,50 33.33% | -0,18 | -0,23 | -0,18 | -0,17 | -0,35 |
| Announcement Date | 29/03/22 | 13/05/22 | 15/08/22 | 01/11/22 | 22/03/23 | 11/05/23 | 11/08/23 | 07/11/23 | 21/03/24 | - | - | - | - | - |
More events
Past sector events for Pyxis Oncology, Inc.
| 03/05/2024 12:00 | GH RESEARCH PLC: Q1 2024 Earnings Release |
| 02/05/2024 21:05 | KURA ONCOLOGY, INC.: Q1 2024 Earnings Release |
| 02/05/2024 21:05 | ZYMEWORKS INC.: Q1 2024 Earnings Release |
| 02/05/2024 21:02 | ARDELYX, INC.: Q1 2024 Earnings Release |
| 02/05/2024 21:01 | LONGBOARD PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 21:01 | ASCENDIS PHARMA A/S: Q1 2024 Earnings Release |
| 02/05/2024 21:00 | ULTRAGENYX PHARMACEUTICAL INC.: Q1 2024 Earnings Release |
| 02/05/2024 16:00 | GENMAB A/S: Q1 2024 Earnings Release |
| 02/05/2024 12:00 | GERON CORPORATION: Q1 2024 Earnings Release |
| 02/05/2024 12:00 | AGIOS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- PYXS Stock
- Calendar Pyxis Oncology, Inc.
